The 5-HT1A antagonist WAY 100635 can block the low-dose locomotor stimulant effects of cocaine

被引：20
|
作者：
Carey, R
Damianopoulos, E
DePalma, G
机构：
[1] VA Med Ctr, Res & Dev 151, Syracuse, NY 13210 USA
[2] SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA
来源：
BRAIN RESEARCH | 2000年 / 862卷 / 1-2期
关键词：
cocaine; locomotion; 5-HT1A receptors; WAY; 100635; dopamine;
D O I：
10.1016/S0006-8993(00)02084-9
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Cocaine treatments of 2.5, 5.0, 10.0 and 15.0 mg/kg induced dose-dependent increases in locomotor behavior. This cocaine-induced increase in locomotion was blocked if the animals were administered the selective 5-HT1A antagonist, WAY 100635 (0.4 mg/kg) prior to the cocaine treatment. The 0.4-mg/kg dose of WAY 100635 did not affect locomotor behavior or alter cocaine availability in brain. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：242 / 246
页数：5
相关论文
共 50 条
  • [31] PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635
    Carson, RE
    Lan, LX
    Watabe, H
    Der, MG
    Adams, HR
    Jagoda, E
    Herscovitch, P
    Eckelman, WC
    NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (05) : 493 - 497
  • [32] Synergistic actions of the 5-HT1A receptor antagonist WAY-100635 and citalopram on male rat ejaculatory behavior
    Ahlenius, S
    Larsson, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 379 (01) : 1 - 6
  • [33] Evaluation of a new F-18 labeled analog of the 5-HT1A antagonist way 100635 for PET.
    Carson, RE
    Lang, L
    Watabe, H
    Der, MG
    Adams, HR
    Jagoda, E
    Endres, CJ
    Herscovitch, P
    Eckelman, WC
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 135P - 136P
  • [34] Tolerance to acute anxiolysis but no withdrawal anxiogenesis in mice treated chronically with 5-HT1A receptor antagonist, WAY 100635
    Cao, BJ
    Rodgers, RJ
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1998, 23 (02): : 247 - 257
  • [35] Rapid up-regulation of 5-HT1A receptor by specific antagonist WAY 100635 in adult rat hippocampus
    Abbas, SY
    Nogueira, MI
    Sawh, RF
    Azmitia, EC
    FASEB JOURNAL, 2003, 17 (05): : A1181 - A1181
  • [36] [F-18]fluoroalkyl analogues of the potent 5-HT1A antagonist WAY 100635: Radiosyntheses and in vivo evaluation
    Wilson, AA
    DaSilva, JN
    Houle, S
    NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (04): : 487 - 490
  • [37] The effects of A 5-HT1A receptor agonist and antagonist on the 5-hydroxytryptamine release in the central nucleus of the amygdala: a microdialysis study with flesinoxan and WAY 100635
    Fokko Bosker
    Dorien Vrinten
    André Klompmakers
    H. Westenberg
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355 : 347 - 353
  • [38] The effects of A 5-HT1A receptor agonist and antagonist on the 5-hydroxytryptamine release in the central nucleus of the amygdala: A microdialysis study with flesinoxan and WAY 100635
    Bosker, F
    Vrinten, D
    Klompmakers, A
    Westenberg, H
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (03) : 347 - 353
  • [39] EFFECTS OF THE SELECTIVE 5-HT1A RECEPTOR ANTAGONIST WAY100635 ON BUSPIRONE-INDUCED ELEVATION IN PLASMA ACTH IN THE CONSCIOUS RAT
    CHILDS, KJ
    CRITCHLEY, DJP
    MIDDLEFELL, VC
    DOURISH, CT
    FASEB JOURNAL, 1995, 9 (03): : A408 - A408
  • [40] Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist
    Fletcher, A
    Forster, EA
    Bill, DJ
    Brown, G
    Cliffe, IA
    Hartley, JE
    Jones, DE
    McLenachan, A
    Stanhope, KJ
    Critchley, DJP
    Childs, KJ
    Middlefell, VC
    Lanfumey, L
    Corradetti, R
    Laporte, AM
    Gozlan, H
    Hamon, M
    Dourish, CT
    BEHAVIOURAL BRAIN RESEARCH, 1996, 73 (1-2) : 337 - 353
12345